Metabolic resuscitation agent

PreclinicalSmall molecule

Metabolic resuscitation agent is one of 3 small molecule programs targeting Microcirculation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MicrocirculationRecruiting

MicrocirculationPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Microcirculation

#DrugCompanyPhaseTrials

Angiomax

BBaxter Healthcare Corporation

Approved

1 2

Compound Danshen Dropping Pills

RRuijin Hospital

Preclinical

1 3

Metabolic resuscitation agent

SSoutheast University, China

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vasoplegia1 trial

Clinical Study of the Effect of Intravenous Vitamin C on the Prognosis and Sublingual Microcirculation in Patients With Vasoplegia Syndrome After Cardiac Surgery.

Completed·SSoutheast University, China·Preclinical·NCT06723626·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Metabolic resuscitation agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metabolic resuscitation agent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metabolic resuscitation agent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Southeast University, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSoutheast University, China

Metabolic resuscitation agent

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vasoplegia1 trial

References

Drug Info

Quick Facts

Related News